isoxazoles has been researched along with abt-737 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, J; Jeon, H; Kim, SW; Koh, GY; Lee, DH; Lee, MH; Park, I; Park, KS; Seo, S; Yang, H | 1 |
1 other study(ies) available for isoxazoles and abt-737
| Article | Year |
|---|---|
HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Cell Line, Tumor; Drug Synergism; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nitrophenols; Piperazines; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Resorcinols; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides; Xenograft Model Antitumor Assays | 2017 |